Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for c…
The End Kidney Deaths Act creates a refundable federal tax credit for individuals who make qualified non-directed living kidney donations.
Donors receive $10,000 for the donation year and each of the following four years (totaling $50,000), with an acceleration to $50,000 upon the donor's death that year.
The credit applies only to anonymous (non‑directed) living kidney donations, is effective for kidneys removed after December 31, 2026, and sunsets after December 31, 2036.
Modest chances: narrow policy with humanitarian appeal but refundable spending and ethical questions make Senate passage and floor consensus uncertain.
Relative to its intended legislative type, this bill is a substantive tax-law change that is reasonably specific about the credit's financial terms and statutory placement but provides limited administrative, fiscal, and oversight detail.
Progressives emphasize lifesaving transplant increases and donor supports
Progressives emphasize lifesaving transplant increases and donor supports
Likely broadly supportive because the credit aims to increase kidney transplants and reduce waitlist deaths.
They will nonetheless press for protections against exploitation, robust donor follow-up care, and equitable access to donation benefits.
Some concerns about marketizing body parts will be moderated because the credit is limited to non‑directed donations and explicitly excluded from being considered a purchase of an organ.
Pragmatically favorable if the bill demonstrably increases transplants and is fiscally managed.
They will weigh life‑saving potential against program cost and legal clarity, and likely seek implementation safeguards, monitoring, and a budgetary score or offsets.
Skeptical or opposed owing to concerns about government incentives for bodily donations, expansion of refundable tax credits, and potential commodification of organs.
Some conservatives may accept reimbursements for expenses, but a multi-year refundable credit is likely viewed as inappropriate federal action.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest chances: narrow policy with humanitarian appeal but refundable spending and ethical questions make Senate passage and floor consensus uncertain.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize lifesaving transplant increases and donor supports
Modest chances: narrow policy with humanitarian appeal but refundable spending and ethical questions make Senate passage and floor consensu…
Relative to its intended legislative type, this bill is a substantive tax-law change that is reasonably specific about the credit's financial terms and statutory placement but provides limited administrative, fiscal, an…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.